Results 61 to 70 of about 11,898 (160)

Lack of Differences in the Pharmacokinetics of Therapeutic Monoclonal Antibodies Between Japanese and Non‐Japanese Individuals

The Journal of Clinical Pharmacology, Volume 66, Issue 8, August 2026.
Abstract Evaluation of the pharmacokinetics (PK) of new drugs in Japanese individuals is regularly requested by the Japanese regulatory agency prior to participation in global clinical trials or for bridging approaches for regulatory approval. However, the need for PK assessments in the Japanese population may be less compelling for monoclonal ...
Paridhi Gupta, Ashish Sharma, Bernd Meibohm   +2 more
wiley   +1 more source

Safety, Pharmacokinetics, Food effect, and Pharmacodynamics of AJM347, a Selective α4β7 Integrin Antagonist: A First‐in‐Human Single‐ and Multiple‐Ascending Dose Study in Healthy Male Volunteers

The Journal of Clinical Pharmacology, Volume 66, Issue 8, August 2026.
Abstract This first‐in‐human study evaluated the safety, pharmacokinetics (PK), food effect, and pharmacodynamics (PD) of AJM347, a novel orally active, selective α4β7 integrin antagonist, in healthy Caucasian and Japanese adult males. The study consisted of three parts.
Tetsuya Koyama, Tatsunori Seki
wiley   +1 more source

Safety and Effectiveness of Dimethyl Fumarate in Japanese Patients With Multiple Sclerosis: Subgroup Analysis of Older Patients and Patients Switching From Fingolimod or Natalizumab Using 2‐Year Post‐Marketing Surveillance Data

Clinical and Experimental Neuroimmunology, Volume 17, Issue 3, August 2026.
In a 2‐year post‐marketing surveillance of Japanese patients with multiple sclerosis, dimethyl fumarate (DMF) showed manageable safety, with no new concerns identified; lymphocyte decreases were more frequent in older patients and those switching from fingolimod.
Ichiro Nakashima, Toshiyuki Fukazawa, Kazumasa Yokoyama, Takashi Yamamura, Hirofumi Ochi, Michihiro Kanda, Yayoi Sato, Ryusuke Sato, Haruki Makioka, Aya Tsuchiya, Takahiko Saida   +10 more
wiley   +1 more source

Natalizumab for the treatment of relapsing multiple sclerosis

Biologics: Targets & Therapy, 2008
Richard A Rudick1, Michael A Panzara21Cleveland Clinic Foundation, Cleveland, OH, USA; 2Biogen Idec, Inc., Cambridge, MA, USAAbstract: Natalizumab is an α4-integrin antagonist approved as monotherapy for patients with relapsing multiple ...
Richard A Rudick, Michael A Panzara
doaj  

A comparative study of fatigue and processing speed in patients with multiple sclerosis treated with natalizumab or rituximab

Multiple Sclerosis Journal - Experimental, Translational and Clinical
Background Fatigue is the most debilitating symptom in patients with multiple sclerosis (MS). Natalizumab and rituximab are the most used MS disease modifying therapies in Sweden, but comparative data on the effect on fatigue is sparse. Objective Primary
Johan Hellgren, Maria Compagno Strandberg, Kristina Källén, Anders Svenningsson   +3 more
doaj   +1 more source

Changes in JC virus-specific T cell responses during natalizumab treatment and in natalizumab-associated progressive multifocal leukoencephalopathy.

PLoS Pathogens, 2012
Progressive multifocal leukoencephalopathy (PML) induced by JC virus (JCV) is a risk for natalizumab-treated multiple sclerosis (MS) patients. Here we characterize the JCV-specific T cell responses in healthy donors and natalizumab-treated MS patients to
Molly R Perkins, Caroline Ryschkewitsch, Julia C Liebner, Maria Chiara G Monaco, Danielle Himelfarb, Sara Ireland, Annelys Roque, Heather L Edward, Peter N Jensen, Gina Remington, Thomas Abraham, Jaspreet Abraham, Benjamin Greenberg, Charles Kaufman, Chris LaGanke, Nancy L Monson, Xiaoning Xu, Elliot Frohman, Eugene O Major, Daniel C Douek   +19 more
doaj   +1 more source

Bridging the Pregnancy Knowledge Gap: A Real‐World Analysis of Medication Use and Drug–Drug Interaction Risk in Crohn's Disease and Multiple Sclerosis

Clinical and Translational Science, Volume 19, Issue 8, August 2026.
ABSTRACT The exclusion of pregnant individuals from clinical trials has resulted in a significant medical knowledge gap for this population. Leveraging real‐world data (RWD) provides a critical window into the prevalence and use of medications during pregnancy.
Jacqueline Williams, Rucha Sane, Amita Joshi, Kit Wun Kathy Cheung, Bianca Vora   +4 more
wiley   +1 more source

Ventricular‐vascular coupling at rest and immediately following maximal exercise in adults with and without multiple sclerosis

Physiological Reports, Volume 14, Issue 15, August 2026.
Abstract Multiple sclerosis (MS) may impair ventricular‐vascular coupling (VVC), a measure of the interaction between the cardiac and vascular systems. We evaluated if VVC differed between individuals with and without MS with similar age‐predicted fitness.
Brooks A. Hibner, Natalia S. Lima, Sara R. Sherman, Robert W. Motl, Julio A. Chirinos, Shane Phillips, Philip S. Clifford, Anthony T. Reder, Tracy Baynard, Bo Fernhall   +9 more
wiley   +1 more source

Bruising following natalizumab infusion for relapsing-remitting multiple sclerosis: a case report

Journal of Medical Case Reports, 2009
Introduction Natalizumab is a new treatment for relapsing-remitting multiple sclerosis. Because of limited experience of this treatment, medical professionals must be alert to possible side effects.
Gatzonis Stylianos, Siatouni Anna
doaj   +1 more source

Impact of Natalizumab on Productivity and Ability to Work in Patients with Multiple Sclerosis in France: The TITAN Study

Neurology and Therapy
Introduction The TITAN study examined changes in productivity, ability to work, and quality of life (QoL) before and after treatment with the high-efficacy therapy natalizumab (TYSABRI®) in patients with multiple sclerosis (MS) in France.
Patrick Vermersch, Arnaud Kwiatkowski, Jérôme de Sèze, Alain Créange, Nathalie Texier, Sophie Fantoni-Quinton, Marilyn Gros, Marta Ruiz, Christine Lebrun-Frenay, on behalf of the TITAN Investigators   +9 more
doaj   +1 more source